Drug intelligence / Profile preview

rhLTα28-171

Development stage: Unknown
Lead developer: Shanghai Pharmaceuticals
Modality: Recombinant Proteins and Enzymes

Overview

**rhLTα28-171 (LT)** is a recombinant high-affinity tumor necrosis factor (TNF) receptor protein developed as a biopharmaceutical agent, likely functioning as a soluble TNF receptor to sequester TNF-alpha and inhibit its pro-inflammatory activity. It is part of a strategic R&D collaboration between Shanghai Pharmaceuticals Holding Co., Ltd. and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., where Shanghai Pharmaceuticals committed RMB180 million over six years for its development alongside other products. The Group holds proprietary intellectual property rights to rhLTα28-171, positioning it as an innovative biologic targeting inflammatory pathways, though specific indications, clinical trial phases, and current status post-2011 are not detailed in available records.

Other names: Recombinant High Affinity TNF Receptor

Targets

TL1A (TNF-like cytokine 1A)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on rhLTα28-171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhLTα28-171.

Explore the full profile